Core Insights - Longeveron Inc. has elected Dr. Roger Hajjar to its Board of Directors, enhancing its leadership in the field of gene and cell therapy [1][7] - Dr. Hajjar is recognized for his contributions to cardiac gene therapy and has initiated multiple clinical trials for cardiovascular diseases [2][4] - The company is advancing its lead product, Lomecel-B™, which has shown potential in treating conditions like hypoplastic left heart syndrome (HLHS) and Alzheimer's disease [3][5] Company Overview - Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines to meet unmet medical needs [5] - The lead investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell therapy derived from the bone marrow of young, healthy adult donors [5] - Lomecel-B™ has received significant FDA designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for its HLHS program [5] Leadership and Strategic Direction - Dr. Hajjar's appointment is part of a planned Board refreshment process aimed at incorporating experienced leaders to enhance the company's knowledge base [7] - The company aims to leverage Dr. Hajjar's expertise to advance its therapeutic development programs, particularly in gene and cell therapy [7]

Dr. Hajjar is an internationally renowned scientific leader in the field of cardiac gene therapy. His laboratory had validated a number of cardiac targets that led to the initiation and completion under his guidance of First-inHuman gene therapy trials in patients with heart failure. He has initiated multiple clinical trials in gene therapy for a variety of cardiovascular diseases. About Longeveron Inc. Investor Contact: Derek Cole Investor Relations Advisory Solutions derek.cole@iradvisory.com "I am deligh ...

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The Company intends to use the net proceeds from the transaction for its ongoing clinical and regulatory development of Lomecel-B™ for the treatment of several disease states and indications, including HLHS and Alzheimer's disease, obtaining regulatory approvals, capital expenditures, working capital and other general corporate purposes. This press release does not constitute an offer to sell or a solicitation of an offer to buy ...

In consideration for the immediate exercise of the existing warrants for cash and the payment of $0.125 per new warrant, the Company issued new unregistered warrants to purchase up to an aggregate of 3,395,782 shares of Class A common stock. The new warrants are immediately exercisable at an exercise price of $2.50 per share and have a term of twenty-four months from the date of issuance. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. T ...

Core Insights - Longeveron Inc. is a clinical stage biotechnology company focused on developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease [2][4] - The company will participate in the Virtual Life Sciences Investor Forum on June 20, 2024, with a webcast available for access on their website [2][3] - Longeveron's lead investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell therapy derived from the bone marrow of young, healthy adult donors, with potential applications across various disease areas [4] Company Overview - Longeveron is developing regenerative medicines to address unmet medical needs, focusing on three pipeline indications: HLHS, Alzheimer's disease, and aging-related frailty [4] - The Lomecel-B™ HLHS program has received three significant U.S. FDA designations: Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation [4]

MIAMI, June 17, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 1,697,891 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in Apr ...

Core Viewpoint - Longeveron Inc. has entered into agreements for the exercise of existing warrants, which will generate approximately $4.4 million in gross proceeds for the company, aimed at supporting its clinical and regulatory development efforts for its lead product, Lomecel-B™ [1][8]. Group 1: Financial Transactions - The company announced the exercise of warrants to purchase 1,697,891 shares of Class A common stock at an exercise price of $2.35 per share, originally issued in April 2024 [1]. - In exchange for the immediate exercise of existing warrants, Longeveron will issue new unregistered warrants to purchase up to 3,395,782 shares of Class A common stock at an exercise price of $2.50 per share, with a term of twenty-four months [2]. - The offering is expected to close on or about June 18, 2024, subject to customary closing conditions [8]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for ongoing clinical and regulatory development of Lomecel-B™, targeting conditions such as hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, as well as for capital expenditures, working capital, and other general corporate purposes [8]. Group 3: Company Overview - Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs, with its lead investigational product being Lomecel-B™, an allogeneic medicinal signaling cell therapy [10]. - The company is pursuing three pipeline indications: HLHS, Alzheimer's disease, and aging-related frailty [10].

Core Insights - Longeveron (NASDAQ:LGVN) stock is experiencing a significant rally due to positive trial news from the ongoing Phase 2 trial of Lomocel-B, a treatment for hypoplastic left heart syndrome (HLHS) [1][2][4] Group 1: Trial Progress and Investor Sentiment - The Phase 2 trial of Lomocel-B is ongoing, with a positive investigator meeting, indicating strong demand for the product as HLHS is often fatal and requires multiple surgeries [2] - Following the initial announcement of the investigator data, LGVN stock surged by 120.7%, with heavy trading volume of approximately 65.3 million shares, significantly above the daily average of 3.3 million shares [3][4] Group 2: Stock Performance - As of Thursday morning, LGVN stock is up 45.9%, with over 17.5 million shares traded, suggesting potential for continued upward momentum throughout the trading day [5]

In fact, as I'm writing this, LGVN stock has already more than doubled on the day. Indeed, as is the case with most such moves in the biotech sector, investors would be right to assume some sort of key headline around one of the company's prospective drugs is driving the tape. LGVN Stock Rockets Higher on Positive Update HLHS is often fatal and is the result of an undeveloped or absent left ventricle at birth. Reconstructive surgeries are needed to allow the right ventricle to do all the work, but given the ...

Longeveron's lead investigational therapeutic candidate is Lomecel-B™, a proprietary, scalable, allogeneic, adult human bone marrow-derived medicinal signaling cell therapy. ELPIS II is enrolling 38 pediatric patients, with enrollment completion anticipated by year end 2024. The clinical trial is being conducted in collaboration with the National Heart, Lung, and Blood Institute (NHLBI) through grants from the National Institutes of Health (NIH). ELPIS II builds on the positive clinical results of ELPIS I. ...